[go: up one dir, main page]

PE20040808A1 - Derivados de urea ciclica como inhibidores de quinasas - Google Patents

Derivados de urea ciclica como inhibidores de quinasas

Info

Publication number
PE20040808A1
PE20040808A1 PE2004000090A PE2004000090A PE20040808A1 PE 20040808 A1 PE20040808 A1 PE 20040808A1 PE 2004000090 A PE2004000090 A PE 2004000090A PE 2004000090 A PE2004000090 A PE 2004000090A PE 20040808 A1 PE20040808 A1 PE 20040808A1
Authority
PE
Peru
Prior art keywords
imidazolidine
trifluoromethanosulfonyl
ilmethyl
trifluoroacetate
phenyl
Prior art date
Application number
PE2004000090A
Other languages
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20040808A1 publication Critical patent/PE20040808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE P ES 0 A 2; R Y R1 SON O, NH; R2 Y R3 SON HIDROGENO, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO Y HETEROARILO EVENTUALMENTE SUBSTITUIDO O R2 Y R3 FORMAN JUNTOS CON EL CARBONO A LOS CUALES ESTAN UNIDOS UN RADICAL CARBOCICLICO O HETEROCICLICO, ENTRE OTROS; A1 ES UN ENLACE SENCILLO, ALQUILO, ALQUENILO, ALQUINILO; Y E Y1 SON H, OCF3, S(O)nCF3, O-CF2-CHF2, -O-CHF2, ENTRE OTROS; Y E Y1 SON H, HALO, OH, NR5R6 ENTRE OTROS; R5 Y R6 SON HIDROGENO, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS O R5 Y R6 FORMAN CON EL N AL CUAL ESTAN UNIDOS UN RADICAL HETEROCICLICO, ENTRE OTROS; A2 REPRESENTAN LOS VALORES DE A1 Y CO Y S02; B2 ES HETEROCICLICO SATURADO O NO SATURADO CONTENIENDO UNO A VARIOS HETEROATOMOS, ENTRE OTROS; Y2 ES H, HALOGENO, HIDROXILO, ALQUILO, ALCOXI, ENTRE OTROS. n ES 0 A 2. SON COMPUESTOS PREFERIDOS TRIFLUOROACETATO DE (S)-5-METIL-1-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)-IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (S)-5-METIL-1-PIRIDIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)- IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (S)-5-METIL-1-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL) IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (R)-4-METIL-3-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)-IMIDAZOLIDINO-2-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE QUINASAS (GRUPO FAK) UTILES PARA TRATAMIENTOS EN ONCOLOGIA
PE2004000090A 2003-01-31 2004-01-22 Derivados de urea ciclica como inhibidores de quinasas PE20040808A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
PE20040808A1 true PE20040808A1 (es) 2004-12-31

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000090A PE20040808A1 (es) 2003-01-31 2004-01-22 Derivados de urea ciclica como inhibidores de quinasas

Country Status (24)

Country Link
EP (1) EP1599464B1 (es)
JP (1) JP4604020B2 (es)
KR (1) KR20050098286A (es)
CN (1) CN1768054A (es)
AR (1) AR042936A1 (es)
AT (1) ATE482207T1 (es)
AU (1) AU2004209319A1 (es)
BR (1) BRPI0407091A (es)
CA (1) CA2513631A1 (es)
DE (1) DE602004029236D1 (es)
FR (1) FR2850652B1 (es)
HR (1) HRP20050679A2 (es)
MA (1) MA27651A1 (es)
ME (1) MEP22608A (es)
MX (1) MXPA05007407A (es)
NO (1) NO20054006L (es)
NZ (1) NZ541270A (es)
PE (1) PE20040808A1 (es)
PL (1) PL377811A1 (es)
RS (1) RS20050657A (es)
RU (1) RU2341523C2 (es)
TW (1) TW200505898A (es)
WO (1) WO2004070050A2 (es)
ZA (1) ZA200505934B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2567135T3 (es) * 2003-08-29 2016-04-20 The Brigham And Women's Hospital, Inc. Derivados de hidantoína como inhibidores de necrosis celular
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
NZ548209A (en) 2003-12-19 2009-07-31 Univ California Methods and materials for assessing prostate cancer thearapies
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
KR101782236B1 (ko) 2005-05-13 2017-09-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
SI2656841T1 (sl) 2006-03-27 2016-11-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljanje raka prostate in bolezni, povezanih z androgenimi receptorji
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
AR069039A1 (es) 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
LT3124481T (lt) 2010-02-16 2018-06-11 Aragon Pharmaceuticals, Inc. Androgeno receptorių moduliatoriai ir jų panaudojimas
EP2655428B1 (en) * 2010-12-21 2022-09-14 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
AU2013323861C1 (en) 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AP2016009368A0 (en) 2014-01-14 2016-08-31 Millennium Pharm Inc Heteroaryls and uses thereof
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
SMT202100723T1 (it) * 2016-07-20 2022-01-10 Novartis Ag Derivati di amminopiridina e loro uso come inibitori selettivi di alk-2
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
KR102247795B1 (ko) * 2017-10-31 2021-05-04 주식회사 펠레메드 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
TW202517640A (zh) * 2023-07-18 2025-05-01 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 用於治療疾病之ｉｇｆ－１ｒ的雜環抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
EE9900481A (et) * 1997-03-03 2000-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6699888B2 (en) * 2000-05-31 2004-03-02 Tanabe Seiyaku Co., Ltd. Inhibitors of αLβ2 mediated cell adhesion
CN101230038A (zh) * 2002-05-16 2008-07-30 拜尔作物科学有限公司 吡啶甲酰胺衍生物及其作为杀虫剂的用途

Also Published As

Publication number Publication date
AU2004209319A1 (en) 2004-08-19
PL377811A1 (pl) 2006-02-20
NO20054006D0 (no) 2005-08-29
ATE482207T1 (de) 2010-10-15
AR042936A1 (es) 2005-07-06
MEP22608A (en) 2010-06-10
WO2004070050A3 (fr) 2005-02-17
JP2006517569A (ja) 2006-07-27
MA27651A1 (fr) 2005-12-01
FR2850652B1 (fr) 2008-05-30
RU2005127335A (ru) 2006-09-10
ZA200505934B (en) 2007-06-27
RS20050657A (sr) 2007-06-04
BRPI0407091A (pt) 2006-01-24
MXPA05007407A (es) 2005-09-12
DE602004029236D1 (de) 2010-11-04
EP1599464B1 (fr) 2010-09-22
EP1599464A2 (fr) 2005-11-30
CN1768054A (zh) 2006-05-03
FR2850652A1 (fr) 2004-08-06
NO20054006L (no) 2005-10-13
CA2513631A1 (fr) 2004-08-19
NZ541270A (en) 2008-11-28
TW200505898A (en) 2005-02-16
KR20050098286A (ko) 2005-10-11
HRP20050679A2 (en) 2006-12-31
WO2004070050A2 (fr) 2004-08-19
JP4604020B2 (ja) 2010-12-22
RU2341523C2 (ru) 2008-12-20

Similar Documents

Publication Publication Date Title
PE20040808A1 (es) Derivados de urea ciclica como inhibidores de quinasas
PE20060556A1 (es) Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
BR0209334A (pt) Aminas n-aroil cìclicas
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20040934A1 (es) Derivados de pirimidina como inhibidores selectivos de tirosina quinasas
CR7454A (es) Compuestos quimicos
ECSP066298A (es) Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3)
ES2590504T3 (es) N-ciclilamidas como nematicidas
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
ES2391373T3 (es) Derivados de quinoleína como inhibidores de la cinasa AXL
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
ATE256681T1 (de) N-heterozyklische derivate als nos inhibitoren
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed